The reiteration of the 'Sector Perform' rating and maintenance of the $6 price target by RBC Capital suggests a neutral outlook on bluebird bio's stock in the short term. This indicates that the analyst believes the stock is fairly valued at its current level, and significant price movements are not anticipated in the immediate future. The confidence level is high due to the specific mention of the company and its price target by a reputable analyst.